Malignant Solid Tumor | Cancer Search

Details 3409 Trials 807 Therapies

A malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include carcinomas and sarcomas. Hematopoietic and lymphoid tissue malignancies are not considered solid neoplasms.

parent conditions

Cancer

Solid Neoplasm

child conditions

Malignant Thyroid Gland Neoplasm

Malignant Reproductive System Neoplasm

Sarcoma

Melanoma

Malignant Head and Neck Neoplasm

Malignant Digestive System Neoplasm

Malignant Cardiovascular Neoplasm

Malignant Endocrine Neoplasm

Malignant Urinary System Neoplasm

Malignant Thoracic Neoplasm

Malignant Retroperitoneal Neoplasm

Malignant Sensory System Neoplasm

Malignant Respiratory System Neoplasm

Carcinoma

Malignant Mixed Neoplasm

Malignant Lipomatous Neoplasm

Malignant Mesothelioma

Blastoma

Malignant Connective and Soft Tissue Neoplasm

Choriocarcinoma

Malignant Nervous System Neoplasm

Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Malignant Germ Cell Tumor

Hemangioblastoma

Malignant Breast Neoplasm

Malignant Peritoneal Neoplasm

Malignant Giant Cell Neoplasm

Rhabdoid Tumor

Malignant Soft Tissue Neoplasm

Malignant Skin Neoplasm

Metastatic Malignant Neoplasm

Malignant Fibrohistiocytic Neoplasm

Neuroepithelial Neoplasm

Malignant Solitary Fibrous Tumor

synonyms

MST

Malignant Solid Neoplasm

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

193 sites for NCT04975308

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

90 sites for NCT04961996

ER Positive, +1 more biomarker

Breast Carcinoma

giredestrant, +1 more drug

hormone therapy

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

267 sites for NCT04784715

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +2 more drugs

targeted therapy

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

145 sites for NCT04736706

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

144 sites for NCT05113251

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +3 more drugs

chemotherapy, +1 more type

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

127 sites for NCT05104866

ER Positive, +2 more biomarkers

Breast Carcinoma

datopotamab deruxtecan

targeted therapy

Show 3409 Trials for Malignant Solid Tumor

lutetium Lu 177 vipivotide tetraxetan

FOLH1 Expression

Prostate Carcinoma